Remdesivir for COVID-19 in Europe: will it provide value for money?

Lancet Respir Med. 2021 Feb;9(2):127-128. doi: 10.1016/S2213-2600(20)30568-3. Epub 2020 Dec 17.

¹ Epidemiology Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain. Electronic address: rafael.dalre@quironsalud.es.
² Center for Health Regulatory Policies, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.
³ Sorbonne University, Internal Medicine Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁴ Université de Paris, Centre of Research in Epidemiology and Statistics (CRESS-UMR1153), Institut National de la Santé et de la Recherche Médicale, Paris, France.
⁵ Centre for Clinical Pharmacology, Institute of Health Informatics, University College London, London, UK.
⁶ Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
⁷ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands.

No abstract available

MeSH terms